The European Patent Office (EPO) has granted a licensed patent to ONK Therapeutics covering CISH knockout (KO) in natural killer (NK) cells, irrespective of the source of the NK cells. The patent includes human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem cells (iPSCs). CISH KO has been shown to improve […]
